Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
M Yan, S Man, L Ma, L Guo, L Huang… - Clinical and Molecular …, 2024 - pmc.ncbi.nlm.nih.gov
Steatotic liver diseases (SLD) are the principal worldwide cause of cirrhosis and end-stage
liver cancer, affecting nearly a quarter of the global population. SLD includes metabolic …
liver cancer, affecting nearly a quarter of the global population. SLD includes metabolic …
Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells
Q Yi, J Yang, Y Wu, Y Wang, Q Cao… - Frontiers in Immunology, 2023 - frontiersin.org
Cirrhosis is a progressive and diffuse liver disease characterized by liver tissue fibrosis and
impaired liver function. This condition is brought about by several factors, including chronic …
impaired liver function. This condition is brought about by several factors, including chronic …
Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids
YH Zhang, R **e, CS Dai, HW Gao, G Zhou, TT Qi… - Journal of …, 2025 - Elsevier
Background & Aims As the first approved medication for metabolic dysfunction-associated
steatohepatitis (MASH), the thyroid hormone receptor-β (THR-β) agonist MGL-3196 …
steatohepatitis (MASH), the thyroid hormone receptor-β (THR-β) agonist MGL-3196 …